These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 22583451

  • 1. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure.
    McKenna C, Walker S, Lorgelly P, Fenwick E, Burch J, Suekarran S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Palmer S.
    Value Health; 2012 May; 15(3):420-8. PubMed ID: 22583451
    [Abstract] [Full Text] [Related]

  • 2. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 May; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G, Solesse A, Beillat M.
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [Abstract] [Full Text] [Related]

  • 5. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2005 Sep; 23(10):1057-72. PubMed ID: 16235978
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

  • 7. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 08; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

  • 8. Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada.
    Thanh NX, Ezekowitz JA, Tran DT, Kaul P.
    Am J Cardiovasc Drugs; 2016 Oct 08; 16(5):365-76. PubMed ID: 27300508
    [Abstract] [Full Text] [Related]

  • 9. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep 08; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 10. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, Mukherjee D.
    Am J Med; 2012 Aug 08; 125(8):817-25. PubMed ID: 22840667
    [Abstract] [Full Text] [Related]

  • 11. Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
    Ademi Z, Pasupathi K, Liew D.
    Medicine (Baltimore); 2016 May 08; 95(18):e3531. PubMed ID: 27149456
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
    Ajani AE, Marwick TH, Krum H.
    Cardiovasc Revasc Med; 2006 May 08; 7(4):234-6. PubMed ID: 17174870
    [Abstract] [Full Text] [Related]

  • 13. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 May 08; 5(5):354-63. PubMed ID: 14503934
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of eplerenone in patients with chronic heart failure.
    Ademi Z, Pasupathi K, Krum H, Liew D.
    Am J Cardiovasc Drugs; 2014 Jun 08; 14(3):209-16. PubMed ID: 24610254
    [Abstract] [Full Text] [Related]

  • 15. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
    Keating GM, Plosker GL.
    Drugs; 2004 Jun 08; 64(23):2689-707. PubMed ID: 15537370
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.
    Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study.
    Heart; 2014 Nov 08; 100(21):1681-7. PubMed ID: 24993605
    [Abstract] [Full Text] [Related]

  • 17. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J.
    Cardiovasc Drugs Ther; 2001 Jan 08; 15(1):79-87. PubMed ID: 11504167
    [No Abstract] [Full Text] [Related]

  • 18. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F.
    Arch Cardiovasc Dis; 2014 Mar 08; 107(3):149-57. PubMed ID: 24630753
    [Abstract] [Full Text] [Related]

  • 19. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
    Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, Seiz M, Katus HA, Nee P, Uhlmann L, Naci H, Atar D.
    Heart Fail Rev; 2020 Mar 08; 25(2):161-171. PubMed ID: 31364027
    [Abstract] [Full Text] [Related]

  • 20. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J, Gerber RA, Roberts C, Gheorghiade M.
    Am J Ther; 2010 Mar 08; 17(5):446-54. PubMed ID: 20844344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.